Surgical oncologists do not understand what tumours are: they remove the tumour and 'clean out' the lymph nodes, which he regards as wrong.
Original statement
عليا بقى بتوع جراحه الاورام جراحه الاورام ده يا عيني ما يفهمش يعني ايه اورام هو بيخش يشيل الورم هو مالوش دعوه بيه وبي بينقي الليمف نودز بينقي الغدد الليمفاويه الغدد الليمفاويه دلوقتي انت بتنقيها
verbatim according to source. Translation by the project; the Arabic wording is authoritative.
Translation
Surgical oncologists do not understand what tumours are: they remove the tumour and 'clean out' the lymph nodes, which he regards as wrong.
Origin
- Source status
- Video transcript (own words)
- Attribution
- Elawady (machine transcript)
- Video
- Dr Diaa Al Awady د ضياء العوضي is live! السيليوليت (Open source)
- Published
- 11 October 2025
- Timestamp
- 0:05:12 (location in the original video’s automatic YouTube caption track; confirms where the words occur, not who speaks)
- Attribution uncertainty
- Transcript is YouTube CC or machine-generated (no timestamps); wording may contain speech-recognition errors. Speaker attribution within live streams/podcasts is not marked in the transcript; the excerpt was judged to be Elawady's own speech from context. Recurrence = number of archive transcripts matching the keyword pattern ['الغدد الليمفاويه|الليمف', 'تشيل|بينقي|استئصال|يشيل'] (approximate; includes re-uploads/clips; 5 distinct text passages).
- Claimed mechanism
Not stated in this excerpt.
- Claimed health effect
Not specified.
- Population concerned
Cancer patients undergoing surgery.
- Geographic restriction by Elawady
none found; he does not limit this statement to a country or to a production system
Diverging source versions
- Source status
- Video transcript (own words)
- Attribution
- Elawady (machine transcript)
- Video
- Dr Diaa Al Awady د ضياء العوضي is live! لايف مفاجيء (Open source)
- Published
- 5 August 2025
- Timestamp
- not available (transcript has no timings)
- Attribution uncertainty
- Further video in which the same statement recurs; no excerpt recorded. Archive transcript without timestamps.
Scientific assessment
Mostly false – Essential parts of the statement are not supported by the evidence or are strongly exaggerated.
Certainty of evidence: moderate – Further research may still affect the assessment.
1. What was claimed?
Surgical oncologists do not understand what tumours are; they remove the tumour and 'clean out' the lymph nodes, which he regards as wrong.
2. What is demonstrably correct?
Part of his criticism matches what oncology itself learned from trials: removing all axillary nodes did not improve survival compared with less extensive surgery over 25 years (I-INTB-05); in women with 1-2 positive sentinel nodes, skipping full axillary dissection was non-inferior for 10-year survival (86.3% vs 83.6%) (I-INTB-06); in melanoma, completion lymph-node dissection did not improve melanoma-specific survival and caused lymphoedema in 24.1% vs 6.3% (I-INTB-07). Arm lymphoedema affects about one in five breast-cancer survivors and is about four times more common after axillary dissection (I-INTB-08).
3. What is wrong or exaggerated?
The claim that surgical oncologists 'do not understand' tumours is a personal judgement, not a finding. The de-escalation of lymph-node surgery came from oncologists' own randomised trials. In all these trials the tumour itself was removed, and sentinel-node biopsy remained because nodal status gives prognostic information (I-INTB-07). Using alternative-only care instead of standard treatment for curable cancers was associated with higher death rates (I-CHM-03).
4. What remains unclear?
How much lymph-node surgery is optimal differs by cancer type; this assessment used breast cancer and melanoma trials.
5. Which studies support it?
I-INTB-05, I-INTB-06, I-INTB-07, I-INTB-08 (support less lymph-node surgery).
6. Which studies contradict it?
I-CHM-03 (against refusing cancer surgery/treatment; it does not address lymph-node surgery itself).
7. What applies to Germany and Europe?
European practice follows these trials (sentinel-node biopsy, less axillary dissection).
8. What is known about Egypt?
The same evidence applies; access to sentinel-node techniques may vary.
9. What practical conclusion is appropriate?
Less lymph-node surgery is appropriate for many patients, and this is decided by oncology teams using trial evidence. It is not a reason to refuse tumour surgery.
Assessment details
- Rationale for certainty of evidence
RCTs show that routine extensive lymph-node dissection does not improve survival in breast cancer and melanoma (I-INTB-05, I-INTB-06, I-INTB-07) and causes lymphoedema (I-INTB-08), which supports part of his criticism. The broader message - that surgical oncologists do not understand tumours and that removing tumours and nodes is wrong - is not supported; these trials all kept tumour removal and sentinel-node staging.
- Source quality
Machine transcript of a live stream; wording may contain recognition errors; meaning checked in context.
- Regional transferability
High; the same trial evidence underlies EU and Egyptian practice.
- Individual exceptions
The need for lymph-node surgery depends on tumour type, stage and node findings.
- Regional scope of the claim
- general (biological/medical)
- Last reviewed
- 25 October 2026 provisional
In plain language
Dr. Elawady said cancer surgeons do not understand tumours and wrongly 'clean out' lymph nodes. Large trials have indeed shown that removing many lymph nodes often does not help survival and can cause lasting arm or leg swelling. Because of these trials, surgeons now remove fewer lymph nodes. But the same trials still removed the tumour, and checking a few 'sentinel' nodes is still useful. Refusing cancer surgery is dangerous.
Studies on this claim
Studies supporting the claim (0)
No studies in this group.
Studies contradicting or limiting the claim (1)
-
Patients who used only alternative medicine for curable cancer died more often
Johnson SB et al.. J Natl Cancer Inst 2018 · PMID 28922780 · DOI 10.1093/jnci/djx145Cohort studyindependent cross-checkabstract only checked★ key studyRisk of death was 2.5 times higher overall and 5.7 times higher for breast cancer.
Does the study support the specific claim? No · Methodological quality: moderate · Certainty of evidence: see overall assessment of the claim
Original publication · Scientific details
Study explained simply
- What did the researchers want to find out?
Compare AM-only vs conventional treatment.
- How was the study done?
Matched registry cohort.
- How many people, animals or samples were studied?
840 matched patients.
- What was actually found?
HR 2.50 for death.
- How large was the observed effect?
HR 5.68 breast cancer.
- What do the results mean in everyday life?
Replacing cancer treatment with alternatives is dangerous.
- What are the study's limitations?
Observational.
- What does it say about Elawady's specific claim?
Contradicts refusing therapy.
- Do the results apply to Germany and Europe?
Moderate.
- What can explicitly not be concluded from this study?
Effects of complementary approaches used alongside treatment.
No study in this group is marked as key.
Studies with mixed or unclear results (4)
-
Removing all armpit lymph nodes did not improve survival
Fisher B et al.. N Engl J Med 2002 · PMID 12192016 · DOI 10.1056/NEJMoa020128Randomised controlled trialindependent cross-checkabstract only checked★ key studyOver 25 years, women without routine axillary dissection survived as long as those with radical mastectomy.
Supports less lymph-node surgery; all arms removed the tumour.
Does the study support the specific claim? Partly · Methodological quality: high · Certainty of evidence: see overall assessment of the claim
Original publication · Scientific details
Study explained simply
- What did the researchers want to find out?
Compare radical vs less extensive breast surgery
- How was the study done?
RCT
- How many people, animals or samples were studied?
1665 women
- What was actually found?
No survival difference
- How large was the observed effect?
HR 1.03-1.08, CIs include 1
- What do the results mean in everyday life?
Taking out more lymph nodes did not make women live longer; the breast tumour was still removed in all groups.
- What are the study's limitations?
Old trial; abstract only
- What does it say about Elawady's specific claim?
Partly supports his criticism of lymph-node 'cleaning'; contradicts rejecting tumour removal.
- Do the results apply to Germany and Europe?
High
- What can explicitly not be concluded from this study?
Cannot conclude that tumour surgery is unnecessary.
-
Fewer lymph nodes removed, same survival
Giuliano AE et al.. JAMA 2017 · PMID 28898379 · DOI 10.1001/jama.2017.11470Randomised controlled trialindependent cross-checkfull text checked★ key studyIn women with 1-2 positive sentinel nodes, skipping full axillary dissection did not worsen 10-year survival.
Supports less lymph-node surgery, not abandoning tumour surgery.
Does the study support the specific claim? Partly · Methodological quality: high · Certainty of evidence: see overall assessment of the claim
Original publication · Scientific details
Study explained simply
- What did the researchers want to find out?
Test whether full lymph-node dissection is needed
- How was the study done?
RCT
- How many people, animals or samples were studied?
891 women randomised (856 analysed)
- What was actually found?
Survival non-inferior without dissection
- How large was the observed effect?
86.3% vs 83.6% at 10 years
- What do the results mean in everyday life?
Oncologists now remove fewer lymph nodes because trials showed it is safe in selected patients.
- What are the study's limitations?
Specific population; trial closed early with fewer patients and deaths than planned
- What does it say about Elawady's specific claim?
Partly supports his point on lymph nodes; contradicts his claim that surgeons 'do not understand'.
- Do the results apply to Germany and Europe?
High
- What can explicitly not be concluded from this study?
Cannot conclude that tumour removal, sentinel-node staging or lymph-node surgery in other situations (mastectomy, more positive nodes, palpable nodes) is unnecessary
-
Full lymph-node removal in melanoma did not extend life
Faries MB et al.. N Engl J Med 2017 · PMID 28591523 · DOI 10.1056/NEJMoa1613210Randomised controlled trialindependent cross-checkfull text checkedCompletion dissection did not improve melanoma-specific survival but caused more lymphoedema.
Supports less lymph-node surgery; nodal staging still valuable.
Does the study support the specific claim? Partly · Methodological quality: high · Certainty of evidence: see overall assessment of the claim
Original publication · Scientific details
Study explained simply
- What did the researchers want to find out?
Test completion lymph-node dissection
- How was the study done?
RCT
- How many people, animals or samples were studied?
1939 randomised patients (1755 per protocol)
- What was actually found?
No survival benefit; more lymphoedema
- How large was the observed effect?
86% vs 86% 3-year survival; lymphoedema 24.1% vs 6.3%
- What do the results mean in everyday life?
Removing more lymph nodes is not always better; doctors changed practice after this trial.
- What are the study's limitations?
Follow-up only about 3.5 years; per-protocol emphasis; requires regular ultrasound surveillance
- What does it say about Elawady's specific claim?
Partly supports his criticism of lymph-node removal.
- Do the results apply to Germany and Europe?
High
- What can explicitly not be concluded from this study?
Cannot conclude that sentinel-node biopsy or tumour removal is unnecessary; observation was safe only with intensive ultrasound follow-up
-
Arm swelling after breast-cancer lymph-node surgery
DiSipio T et al.. Lancet Oncol 2013 · PMID 23540561 · DOI 10.1016/S1470-2045(13)70076-7Meta-analysisindependent cross-checkabstract only checkedAbout 1 in 5 survivors develop arm lymphoedema; risk is about four times higher after full axillary dissection.
Supports harm of lymph-node removal.
Does the study support the specific claim? Partly · Methodological quality: moderate · Certainty of evidence: see overall assessment of the claim
Original publication · Scientific details
Study explained simply
- What did the researchers want to find out?
Estimate lymphoedema incidence
- How was the study done?
Meta-analysis
- How many people, animals or samples were studied?
72 studies
- What was actually found?
16.6% overall; 19.9% after dissection vs 5.6% after sentinel biopsy
- How large was the observed effect?
about 4-fold
- What do the results mean in everyday life?
Removing many lymph nodes often causes lasting arm swelling.
- What are the study's limitations?
Heterogeneous studies; abstract only
- What does it say about Elawady's specific claim?
Supports his concern about lymph-node removal as a harm.
- Do the results apply to Germany and Europe?
High
- What can explicitly not be concluded from this study?
Cannot conclude that lymph-node surgery never benefits patients.
No study in this group is marked as key.
Regional context
Germany / EU
European practice follows these trials (sentinel-node biopsy, less axillary dissection).
Egypt
The same evidence applies; access to sentinel-node techniques may vary.
What applies in my country?
General scientific assessment
Mostly false Routine extensive lymph-node removal has been scaled back on the basis of trials, but removing the tumour remains an essential part of cancer treatment.
This statement concerns biological or medical relationships. The scientific assessment above applies regardless of the country; country-specific food data do not change it.
References
- Use of Alternative Medicine for Cancer and Its Impact on Survival.. Johnson SB et al.. J Natl Cancer Inst 2018 · PMID 28922780 · DOI 10.1093/jnci/djx145
- Twenty-five-year follow-up of a randomized trial comparing radical mastectomy, total mastectomy, and total mastectomy followed by irradiation.. Fisher B et al.. N Engl J Med 2002 · PMID 12192016 · DOI 10.1056/NEJMoa020128
- Effect of Axillary Dissection vs No Axillary Dissection on 10-Year Overall Survival Among Women With Invasive Breast Cancer and Sentinel Node Metastasis: The ACOSOG Z0011 (Alliance) Randomized Clinical Trial.. Giuliano AE et al.. JAMA 2017 · PMID 28898379 · DOI 10.1001/jama.2017.11470
- Completion Dissection or Observation for Sentinel-Node Metastasis in Melanoma.. Faries MB et al.. N Engl J Med 2017 · PMID 28591523 · DOI 10.1056/NEJMoa1613210
- Incidence of unilateral arm lymphoedema after breast cancer: a systematic review and meta-analysis.. DiSipio T et al.. Lancet Oncol 2013 · PMID 23540561 · DOI 10.1016/S1470-2045(13)70076-7